Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 10/20 | 0.69 |
| ▸ | BTK | Q06187 | 4/20 | 0.69 |
| ▸ | ITK | Q08881 | 4/20 | 0.69 |
| ▸ | JAK2 | O60674 | 1/20 | 0.69 |
| ▸ | LYN | P07948 | 1/20 | 0.69 |
| ▸ | TEC | P42680 | 1/20 | 0.69 |
| ▸ | TXK | P42681 | 1/20 | 0.69 |
| ▸ | BMX | P51813 | 1/20 | 0.69 |
| ▸ | JAK3 | P52333 | 1/20 | 0.69 |
| ▸ | CD69 | Q07108 | 1/20 | 0.69 |
| ▸ | SYK | P43405 | 8/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29431539 | 1.00 | EGFR (0.69) | EGFRBTKITKJAK2LYN | |
| SCHEMBL29411924 | 0.90 | EGFR (0.72) | EGFRBTKITKJAK2LYN | |
| SCHEMBL28718244 | 0.90 | EGFR (0.72) | EGFRBTKITKJAK2LYN | |
| SCHEMBL12518394 | 0.89 | EGFR (0.73) | EGFRBTKITKJAK2LYN | |
| SCHEMBL12518393 | 0.89 | EGFR (0.73) | EGFRBTKITKJAK2LYN | |
| SCHEMBL30843981 | 0.88 | EGFR (0.72) | EGFRBTKITKJAK2LYN | |
| SCHEMBL28711237 | 0.88 | EGFR (0.72) | EGFRBTKITKJAK2LYN | |
| SCHEMBL12518395 | 0.85 | EGFR (0.68) | EGFRBTKITKJAK2LYN | |
| SCHEMBL29665636 | 0.84 | SYK (0.77) | EGFRBTKITKJAK2LYN | |
| SCHEMBL27020093 | 0.84 | SYK (0.77) | EGFRBTKITKJAK2LYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2986319-A1 | COMBINATION THERAPY COMPRISING A TOR KINASE INHIBITOR AND N-(3-(5-FLUORO-2-(4-(2-METHOXYETHOXY)PHENYLAMINO)PYRIMIDIN-4-YLAMINO)PHENYL)ACRYLAMIDE FOR TREATING CANCER | Signal Pharmaceuticals, LLC (US) | 2016-02-24 | — | — | EP | disclosed |
| WO-2014172430-A1 | COMBINATION THERAPY COMPRISING A TOR KINASE INHIBITOR AND N-(3-(5-FLUORO-2-(4-(2-METHOXYETHOXY)PHENYLAMINO)PYRIMIDIN-4-YLAMINO)PHENYL)ACRYLAMIDE FOR TREATING CANCER | SIGNAL PHARMACEUTICALS, LLC (US) | 2014-10-23 | — | — | WO | disclosed |